Tarsus Pharmaceuticals, Inc.
TARSNasdaq
$59.85
↑ +3.7%Jul 17 close · end-of-day
Price
1Y↑ +44.0%
End-of-day closes; the latest point is the live 15-min-delayed price · split & dividend adjusted · chart by TradingView
Key statistics
Market Cap
$2.6B
Enterprise Value
$2.3B
P/E
—
P/S
4.8
P/B
7.4
EV/EBITDA
—
PEG
—
FCF Yield
-1.2%
Dividend Yield
—
Revenue (TTM)
$535.1M
Net Income (TTM)
-$47.8M
Free Cash Flow (TTM)
-$31.5M
Gross Margin
—
Operating Margin
-9.5%
Net Margin
-8.9%
ROE
-13.7%
ROIC
-122.3%
Debt / Equity
0.2
Net Cash
$316.1M
Return 1Y
+44.6%
Earnings
TARS Q1 2026 Earnings
Period ends 2026-03-31
MetricActualYoY
Revenue$162.1M↑ +106.9%
Diluted EPS-$0.16↓ -75.0%
Actuals from SEC filings; YoY vs the year-ago quarter. Analyst estimates & surprise require a data feed (coming soon).
Financial statements
| Line item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Revenue | $0.00 | $57.0M | $25.8M | $17.4M | $183.0M | $451.4M |
| Gross profit | — | — | — | — | — | — |
| Operating income | -$27.0M | -$12.2M | -$62.7M | -$143.2M | -$120.6M | -$71.0M |
| Net income | -$26.8M | -$13.8M | -$62.1M | -$136.0M | -$116.0M | -$66.0M |
| Diluted EPS | -$4.32 | -$0.67 | -$2.52 | -$4.62 | -$3.07 | -$1.59 |
| Operating cash flow | -$21.1M | $3.7M | -$49.0M | -$117.5M | -$83.0M | -$12.5M |
| Free cash flow | -$21.6M | $3.2M | -$49.5M | -$119.0M | -$84.6M | -$22.3M |
| Gross margin | — | — | — | — | — | — |
| Operating margin | — | -21.3% | -242.9% | -820.5% | -65.9% | -15.7% |
| Net margin | — | -24.2% | -240.5% | -779.5% | -63.4% | -14.6% |
| Line item | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $40.8M | $48.1M | $66.4M | $78.3M | $102.7M | $118.7M | $151.7M | $162.1M |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | -$33.3M | -$25.2M | -$24.4M | -$26.3M | -$22.2M | -$14.5M | -$8.0M | -$6.1M |
| Net income | -$33.3M | -$23.4M | -$23.6M | -$25.1M | -$20.3M | -$12.6M | -$8.0M | -$7.0M |
| Diluted EPS | -$0.88 | -$0.61 | -$0.57 | -$0.64 | -$0.48 | -$0.30 | -$0.17 | -$0.16 |
| Operating cash flow | -$14.4M | -$8.7M | -$22.2M | -$20.7M | -$29.4M | $18.3M | $19.3M | -$24.7M |
| Free cash flow | -$15.4M | -$8.9M | -$22.3M | -$21.2M | -$30.4M | $16.3M | $13.0M | -$30.5M |
| Gross margin | — | — | — | — | — | — | — | — |
| Operating margin | -81.6% | -52.3% | -36.8% | -33.5% | -21.6% | -12.2% | -5.3% | -3.8% |
| Net margin | -81.6% | -48.7% | -35.5% | -32.1% | -19.8% | -10.6% | -5.2% | -4.3% |
Company news
Coming soonHeadlines for TARS will appear here once the news feed is connected.
Analyst estimates
Coming soonConsensus revenue & EPS estimates and price targets will appear here once a forward-estimates data feed is connected.
Insider transactions
No insider transactions in the last 12 months.
No insider transactions on file.
Fundamentals & filings from SEC EDGAR. Prices adjusted for splits & dividends. Not investment advice.